Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study

Abstract Background To compare the real-world efficacy and safety of bispecific antibodies (BsAbs, PD-1/CTLA-4) versus PD-1 inhibitors (ICIs), each combined with platinum-based chemotherapy ± bevacizumab, as first-line treatment for persistent, recurrent, or metastatic cervical cancer (p/r/m CC). Me...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Xin Wang, Yaqin Wu, Jian Huang, Dan Zong, Xia He
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer 2025-10-01
Serija:	Cancer Immunology, Immunotherapy
Teme:	Cadonilimab QL1706 PD-1/CTLA-4 bispecific antibody Cervical cancer Immune checkpoint inhibitors
Online dostop:	https://doi.org/10.1007/s00262-025-04204-y
Oznake:	Označite Brez oznak, prvi označite!